Building an inclusive, cross-cutting research immunology and immune engineering community Once a week, Kelly McNagny sits in on meetings with medical doctors at St. Paul’s Hospital’s Centre for Heart and… Read More
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary… Read More
Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy Latest results of the Phase 3 IKEMA trial demonstrate the longest median progression free survival… Read More
Expands rare cannabinoid portfolio with the addition of CBT and CBDV Strengthens IP with publication of a patent application for novel cannabinoid analogs Advances the pharmaceutical drug development programs in… Read More
RADNOR, Pa. — The board of directors of Avantor, Inc. (NYSE: AVTR) a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and… Read More
